PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

• Status: Recruiting
• Trial end date: 2024-04-01

Summary

Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.

• Phase: Phase 4

Details

• Lead Sponsor: Rambam Health Care Campus
• Collaborators: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi; Canadian Institutes of Health Research (CIHR); Emek Medical Center; Hadassah Medical Organization; Hospital Universitario Virgen Macarena; Istituti Ospitalieri di Cremona; Jewish General Hospital; Laniado Hospital; McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre; Meir Medical Center; Rabin Medical Center; Soroka University Medical Center; Tel Aviv Medical Center; The Baruch Padeh Medical Center, Poriya; The Chaim Sheba Medical Center; Università di Pisa, Cisanello Hospital; Universita di Verona; University of Milan; University of Modena and Reggio Emilia
• Treatments: Cephalosporins; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins